For example, Hernandez S et al demonstrated that loss of HPK1 function promotes anti-tumor activity in a mouse model, which could be enhanced by concurrent administration of an anti-PD-L1 antibody, suggesting that these two inhibitory pathways are non-overlapping [16]. Here, MAP4K1 is linked to neoplasm.